Skip to main content
Solid Tumor Thoracic Cancer

Thoracic Cancer

Open Access Lung Cancer Case Study

A challenging diagnosis of lung cancer

Although uncommon, lung cancer in patients with granulomatosis with polyangiitis can be difficult to diagnose due to similarities in imaging findings.

Development of bronchopleural fistula after neoadjuvant immunochemotherapy

Bronchopleural fistula is a rare but potentially fatal complication that can occur after surgery in patients receiving neoadjuvant immunochemotherapy for stage III NSCLC.

Severe megaloblastic anemia related to erlotinib

Open Access NSCLC Case Study

The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.

Trial reassures on SABR use in NSCLC patients with ILD

14-03-2024 NSCLC News

Phase 2 data point to a favorable benefit–risk balance of stereotactic ablative radiotherapy in many patients with early-stage NSCLC and interstitial lung disease.

Managing malignant pleural effusion

Open Access Pleural Effusion Review

Great progress has been made in developing strategies to manage malignant pleural effusion, but these still primarily focus on optimal drainage. More research is needed to advance understanding of mechanistic drivers and develop targeted therapies.

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
NSCLC Podcast

Episode 7: A deep dive into ADAURA

The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC. 

We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.

Dr. Luis Paz-Ares

Current Reviews

Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review

Open Access Lung Cancer Review

Inequitable access to care continues to hinder improvements in diagnosis and treatment of lung cancer. This review describes healthcare disparities in the changing landscape of non–small cell lung cancer (NSCLC) in the United States, focusing on …

Liquid profiling for patients with advanced cancer is ready for clinical integration

Open Access NSCLC short review

Molecular profiling of circulating tumor DNA (ctDNA) to guide treatment decisions has found its way into routine management of patients with advanced cancer. This represents a pivotal advancement in precision oncology, offering a non-invasive and …

Abnormal progression of brain herniation into intraosseous arachnoid granulation in a patient with metastatic lung carcinoma

Arachnoid granulations (AGs) are protrusion of arachnoid membrane into dural sinuses. They function the transport of cerebrospinal fluid (CSF) from subarachnoid space into the venous system. AGs frequently protrude into the dural venous sinuses …

A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Open Access NSCLC Review

According to current guidelines, targeted therapy with a combination of BRAF plus MEK inhibitors is the preferred first-line treatment for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). In the open-label …

Biomarkers Podcast

Episode 5: Next-generation sequencing

Emerging biomarkers in thyroid and non-small cell lung cancers

Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this podcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint.

This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.

Prof. Andrew Beggs
Developed by: Springer Healthcare

Case Studies

A challenging diagnosis of lung cancer

Open Access Lung Cancer Case Study

Although uncommon, lung cancer in patients with granulomatosis with polyangiitis can be difficult to diagnose due to similarities in imaging findings.

Development of bronchopleural fistula after neoadjuvant immunochemotherapy

Bronchopleural fistula is a rare but potentially fatal complication that can occur after surgery in patients receiving neoadjuvant immunochemotherapy for stage III NSCLC.

Severe megaloblastic anemia related to erlotinib

Open Access NSCLC Case Study

The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.

Webinar (Link opens in a new window)

1.25 AMA PRA Category 1 Credit(s)

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME

eLearning | Interviews | Digital Treatment Map (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.
Developed by: Springer Healthcare IME

Digital Treatment Map (Link opens in a new window)

Practical, expert-led digital map designed to guide treatment of ALK- and ROS1-mutation positive NSCLC.

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME

Related topics

Although uncommon, lung cancer in patients with granulomatosis with polyangiitis can be difficult to diagnose due to similarities in imaging findings.

Read more

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Further Reading

Liquid profiling for patients with advanced cancer is ready for clinical integration

Open Access NSCLC short review

Molecular profiling of circulating tumor DNA (ctDNA) to guide treatment decisions has found its way into routine management of patients with advanced cancer. This represents a pivotal advancement in precision oncology, offering a non-invasive and …

Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Open Access NSCLC Leading Article

Kristen Rat Sarcoma viral oncogene (KRAS) mutations are one of the most common oncogenic drivers found in 12–14% of non-small cell lung cancer (NSCLC) and 4% of colorectal cancer tumors. Although previously difficult to target, sotorasib and …

Postoperative pulmonary function of patients with lung cancer and interstitial lung abnormalities

Open Access NSCLC Original Article

Interstitial lung abnormalities [ILAs] are defined as those observed on chest computed tomography [CT] images that are associated with interstitial lung disease or pulmonary fibrosis in individuals without a clinical diagnosis [ 1 ]. Patients with …